pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

25,422 catalysts · 5,777 approval · 5,000 device 510k · 4,728 grant · 3,126 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 97 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2022-08-24×clear all
type
  • approval5,777
  • device 510k5,000
  • grant4,728
  • 8k filing3,126
  • device pma2,000
  • device recall2,000
recall
1,126
  • device adverse event1,000
  • earnings583
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Oct 17, 2022

    1
    ›Oct 21, 2022approval1391d agoRINVOQ (UPADACITINIB) — FDA approvalupadacitinib tartrate ER

    Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →upadacitinib tartrate ER →fda approvals ↗

    Week of Oct 24, 2022

    15
    ›Oct 24, 2022approval1388d agoDOXYCYCLINE HYCLATE — FDA approvalDOXYCYCLINE HYCLATE

    Sponsor: AMNEAL. Form: TABLET. Route: ORAL

    full page →DOXYCYCLINE HYCLATE →fda approvals ↗
    ›Oct 24, 2022approval1388d agoIGALMI (DEXMEDETOMIDINE HYDROCHLORIDE) — FDA approvaldexmedetomidine

    Sponsor: BIOXCEL. Form: FILM. Route: BUCCAL, SUBLINGUAL

    full page →dexmedetomidine →fda approvals ↗
    ›Oct 24, 2022approval1388d agoVEKLURY (REMDESIVIR) — FDA approvalremdesivir

    Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS

    full page →remdesivir →fda approvals ↗
    ›Oct 25, 2022approval1387d agoVIGABATRIN — FDA approvalVIGABATRIN

    Sponsor: GRANULES. Form: FOR SOLUTION. Route: ORAL

    full page →VIGABATRIN →fda approvals ↗
    ›Oct 25, 2022approval1387d agoTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalteclistamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →teclistamab →fda approvals ↗
    ›Oct 25, 2022approval1387d agoATORVASTATIN CALCIUM — FDA approvalSciegen Pharmaceuticals Inc

    Sponsor: SCIEGEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 26, 2022approval1386d agoVIGABATRIN — FDA approvalPyros Pharmaceuticals Inc.

    Sponsor: ALKEM LABS LTD. Form: FOR SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 26, 2022approval1386d agoEPRONTIA (TOPIRAMATE) — FDA approvaltopiramate ER

    Sponsor: AZURITY. Form: SOLUTION. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Oct 27, 2022approval1385d agoVIGABATRIN — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA PHARMS USA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 27, 2022approval1385d agoVIGABATRIN — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA PHARMS USA. Form: FOR SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 28, 2022approval1384d agoVIGABATRIN — FDA approvalInvaGen Pharmaceuticals Inc

    Sponsor: INVAGEN PHARMS. Form: FOR SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 28, 2022approval1384d agoVIGABATRIN — FDA approvalInvaGen Pharmaceuticals Inc

    Sponsor: INVAGEN PHARMS. Form: FOR SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 28, 2022approval1384d agoXYZAL ALLERGY 24HR (LEVOCETIRIZINE DIHYDROCHLORIDE) — FDA approvalSanofi

    Sponsor: CHATTEM SANOFI. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 28, 2022approval1384d agoPADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approvalenfortumab vedotin

    Sponsor: ASTELLAS. Form: INJECTABLE. Route: INJECTION

    full page →enfortumab vedotin →fda approvals ↗
    ›Oct 28, 2022approval1384d agoLEUPROLIDE ACETATE — FDA approvalLEUPROLIDE ACETATE

    Sponsor: AMNEAL. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →LEUPROLIDE ACETATE →fda approvals ↗

    Week of Oct 31, 2022

    8
    ›Nov 1, 2022approval1380d agoDATSCAN (IOFLUPANE I-123) — FDA approval

    Sponsor: GE HLTHCARE INC. Form: SOLUTION. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Nov 1, 2022approval

    Week of Nov 7, 2022

    12
    ›Nov 8, 2022approval1373d agoVIGABATRIN — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: FOR SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Nov 8, 2022approval

    Week of Nov 14, 2022

    6
    ›Nov 15, 2022approval1366d agoBUDESONIDE — FDA approvalbudesonide DR

    Sponsor: RISING. Form: CAPSULE, DELAYED RELEASE. Route: ORAL

    full page →budesonide DR →fda approvals ↗
    ›Nov 15, 2022approval

    Week of Nov 21, 2022

    8
    ›Nov 21, 2022approval1360d agoVERQUVO (VERICIGUAT) — FDA approvalMerck & Co., Inc.

    Sponsor: MSD. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 22, 2022approval
    ← prev
    page 4 of 509
    next →
    1380d ago
    LANSOPRAZOLE — FDA approvallansoprazole DR

    Sponsor: DEXCEL. Form: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE. Route: ORAL

    full page →lansoprazole DR →fda approvals ↗
    ›Nov 1, 2022approval1380d agoZEGERID OTC (OMEPRAZOLE) — FDA approvalCovis Pharmaceuticals Inc (Inactive)

    Sponsor: RILEY CONSUMER. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Nov 1, 2022approval1380d agoIRBESARTAN — FDA approvalIRBESARTAN

    Sponsor: JUBILANT GENERICS. Form: TABLET. Route: ORAL

    full page →IRBESARTAN →fda approvals ↗
    ›Nov 2, 2022approval1379d agoDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval(daratumumab + hyaluronidase (human recombinant))

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →(daratumumab + hyaluronidase (human recombinant)) →fda approvals ↗
    ›Nov 2, 2022approval1379d agoLANOXIN PEDIATRIC (DIGOXIN) — FDA approvalDIGOXIN

    Sponsor: AZURITY. Form: INJECTABLE. Route: INJECTION

    full page →DIGOXIN →fda approvals ↗
    ›Nov 4, 2022approval1377d agoENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approvaltrastuzumab deruxtecan

    Sponsor: DAIICHI SANKYO. Form: INJECTABLE. Route: INJECTION

    full page →trastuzumab deruxtecan →fda approvals ↗
    ›Nov 4, 2022approval1377d agoRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalamivantamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →amivantamab →fda approvals ↗
    1373d ago
    VIGABATRIN — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: FOR SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Nov 8, 2022approval1373d agoVIGABATRIN — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: FOR SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Nov 8, 2022approval1373d agoCARBAMAZEPINE — FDA approvalcarbamazepine ER

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →carbamazepine ER →fda approvals ↗
    ›Nov 8, 2022approval1373d agoERLEADA (APALUTAMIDE) — FDA approvalapalutamide

    Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

    full page →apalutamide →fda approvals ↗
    ›Nov 8, 2022approval1373d agoERLEADA (APALUTAMIDE) — FDA approvalapalutamide

    Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

    full page →apalutamide →fda approvals ↗
    ›Nov 8, 2022approval1373d agoLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalcemiplimab

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INTRAVENOUS

    full page →cemiplimab →fda approvals ↗
    ›Nov 9, 2022approval1372d agoZTALMY (GANAXOLONE) — FDA approvalganaxolone

    Sponsor: IMMEDICA PHARMA. Form: SUSPENSION. Route: ORAL

    full page →ganaxolone →fda approvals ↗
    ›Nov 9, 2022approval1372d agoZTALMY (GANAXOLONE) — FDA approvalganaxolone

    Sponsor: IMMEDICA PHARMA. Form: SUSPENSION. Route: ORAL

    full page →ganaxolone →fda approvals ↗
    ›Nov 10, 2022approval1371d agoIMFINZI (DURVALUMAB) — FDA approvalASTRAZENECA PLC

    Sponsor: ASTRAZENECA UK LTD. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Nov 13, 2022approval1368d agoDAPTOMYCIN — FDA approvalDaptomycin Novo

    Sponsor: MEITHEAL. Form: POWDER. Route: INTRAVENOUS

    full page →Daptomycin Novo →fda approvals ↗
    ›Nov 13, 2022approval1368d agoDAPTOMYCIN — FDA approvalDaptomycin Novo

    Sponsor: MEITHEAL. Form: POWDER. Route: INTRAVENOUS

    full page →Daptomycin Novo →fda approvals ↗
    1366d ago
    HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: WES PHARMA INC. Form: SOLUTION. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Nov 16, 2022approval1365d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalIGC Pharma, Inc.

    Sponsor: SUN PHARM. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›Nov 16, 2022approval1365d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalIGC Pharma, Inc.

    Sponsor: SUN PHARM. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›Nov 16, 2022approval1365d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalIGC Pharma, Inc.

    Sponsor: PHARMOBEDIENT. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›Nov 17, 2022approval1364d agoTRULICITY (DULAGLUTIDE) — FDA approvaldulaglutide

    Sponsor: ELI LILLY AND CO. Form: INJECTABLE. Route: INJECTION

    full page →dulaglutide →fda approvals ↗
    1359d ago
    ACTIQ (FENTANYL CITRATE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: CEPHALON. Form: TROCHE/LOZENGE. Route: TRANSMUCOSAL

    full page →fda approvals ↗
    ›Nov 22, 2022approval1359d agoFENTORA (FENTANYL CITRATE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: CEPHALON. Form: TABLET. Route: BUCCAL, SUBLINGUAL

    full page →fda approvals ↗
    ›Nov 23, 2022approval1358d agoATROPINE SULFATE — FDA approvalATROPINE SULFATE

    Sponsor: ACCORD HLTHCARE. Form: SOLUTION. Route: INTRAVENOUS

    full page →ATROPINE SULFATE →fda approvals ↗
    ›Nov 23, 2022approval1358d agoMETHADOSE (METHADONE HYDROCHLORIDE) — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: SPECGX LLC. Form: TABLET. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Nov 23, 2022approval1358d agoMETHADOSE (METHADONE HYDROCHLORIDE) — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: SPECGX LLC. Form: TABLET. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Nov 23, 2022approval1358d agoMETHADOSE (METHADONE HYDROCHLORIDE) — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: SPECGX LLC. Form: TABLET. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Nov 23, 2022approval1358d agoMETHADOSE (METHADONE HYDROCHLORIDE) — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: SPECGX LLC. Form: TABLET. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    $ABBV249.50+0.61%
    $BTAI0.9215-10.53%
    $MRK130.88-0.03%
    $AMRX17.10-4.36%
    $SNY43.56+0.20%
    $GILD136.30+2.44%
    $AMRX17.10-4.36%
    $AMRX17.10-4.36%
    $AMRX17.10-4.36%
    $AMRX17.10-4.36%
    $IGC0.2670+0.41%
    $IGC0.2670+0.41%
    $REGN802.21-0.72%
    $AZN158.75-1.95%
    $IGC0.2670+0.41%
    $IGC0.2670+0.41%
    $LLY1223.99-0.64%